DDInter1936 DDInter1376
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vinblastine {u} (Compound) resembles {v} (Compound) Vindesine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinblastine {u} (Compound) treats {v} (Disease) kidney cancer
Vinblastine {u} (Compound) binds {v} (Gene) TUBB3
Vinblastine {u} (Compound) upregulates {v} (Gene) OSBPL2
Vinblastine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinblastine {u} (Compound) downregulates {v} (Gene) TMEM168
Vinblastine {u} (Compound) causes {v} (Side Effect) Paraesthesia
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Vinblastine (Compound) resembles Vindesine (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Vinblastine (Compound) treats kidney cancer (Disease)
Vinblastine (Compound) binds TUBB3 (Gene)
Vinblastine (Compound) upregulates OSBPL2 (Gene)
Vinblastine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinblastine (Compound) downregulates TMEM168 (Gene)
Vinblastine (Compound) causes Paraesthesia (Side Effect)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil